 Home > Medical News > Latest Medical News > Huadong Medicine: ADC's new drug treatment of ovarian cancer has reached the primary end point in overseas key clinical trials

Huadong Medicine: ADC's new drug treatment of ovarian cancer has reached the primary end point in overseas key clinical trials

 Last Update: 2022-01-12
 Source: Internet
 Author: User

Tags

2 3 dihydroxypropanal

7 8 simplified

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On December 1, Huadong Medicine issued an announcement stating that the US key single-arm clinical trial (SORAYA trial) of the new ADC drug IMGN853 (Mirvetuximab Soravtansine) developed in cooperation with ImmunoGen, Inc.

IMGN853 is the world’s first ADC drug candidate for folate receptor α (FRα) positive ovarian cancer.

Brief introduction of Mirvetuximab soravtansine (picture source: ImmunoGen official website)

On October 20, 2020, Huadong Medicine and ImmunoGen of the United States reached an agreement to obtain the exclusive clinical development and commercialization rights of IMGN853 in Greater China

The announcement showed that the SORAYA trial evaluated the safety and effectiveness of IMGN853 as a single-agent treatment of platinum-resistant ovarian cancer with high FRα expression.

As of November 16, 2021, the median follow-up time of the trial was 8.

It is worth noting that in June this year, Rongchang Biotechnology obtained the conditional approval of NMPA for the innovative ADC gastric cancer drug injection vedicitumumab.

At present, the first clinical trial application of Huadong Medicine IMGN853 in China has been approved by NMPA in March 2021, including the above-mentioned international multi-center phase III study and an evaluation of safety, tolerability and pharmacokinetics in Chinese adult patients The first phase of the study

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.